miR-140-5p Alleviates The Aggressive Progression Of Wilms’ Tumor Through Directly Targeting TGFBR I Gene [Retraction]
Wang H, Lou C, Ma N. miR-140-5p alleviates the aggressive progression of Wilms’ tumor through directly targeting TGFBR I gene. Cancer Manage Res. 2019;11:1641–1651.
The Editor-in-Chief and Publisher of Cancer Management and Research wish to retract the published article.
Following publication, concerns were raised to the Editor in-Chief regarding the Wilms’ tumor cell lines described in the study.
Upon investigation it was found the human Wilms’ tumor cell lines used in the present study, G-401 and SK-NEP-1, had been wrongly attributed and are not, in fact, Wilms’ tumor cell lines as claimed. The cell line, G-401, has been shown to be a rhabdoid tumor cell line of the kidney and has been reclassified, accordingly, in the American Tissue Culture Collection (ATCC) (https://www.atcc.org/Products/All/CRL-1441.aspx). The cell line, SK-NEP-1 has also been investigated and was found to have a close relationship with the Ewing sarcoma cell line, not theWilms’ tumor cell line as previously indicated.
Based on this information the Editor-in-Chief has determined the results and findings of the present study are no longer valid.
This retraction relates to this paper
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]